Akari Therapeutics Plc Price/Book
Cos'è Price/Book di Akari Therapeutics Plc?
Price/Book di Akari Therapeutics Plc è 74.96
Qual è la definizione di Price/Book?
Il rapporto Price to book rappresenta il rapporto tra il valore delle azioni di una società e il valore contabile per azione.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Price/Book di aziende nel Health Care settore su NASDAQ rispetto a Akari Therapeutics Plc
Cosa fa Akari Therapeutics Plc?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Aziende con price/book simili a Akari Therapeutics Plc
- Splunk ha Price/Book di 74.10
- CG Power and Industrial Solutions ha Price/Book di 74.12
- Zenith ha Price/Book di 74.70
- BioVie ha Price/Book di 74.82
- BioVie ha Price/Book di 74.82
- Plexus plc ha Price/Book di 74.82
- Akari Therapeutics Plc ha Price/Book di 74.96
- Iron Mountain ha Price/Book di 75.49
- Argo Blockchain plc ha Price/Book di 75.54
- Immunomedics ha Price/Book di 75.71
- Cornerstone FS Plc ha Price/Book di 75.80
- Loop Insights ha Price/Book di 77.31
- Aqua Bio Technology ASA ha Price/Book di 77.50